



PTO/SB/08A&B (08-03)

Substitute for form 1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/979,539		
		Filing Date	November 20, 2001		
		First Named Inventor	Pastan, Ira H.		
		Art Unit	1642		
		Examiner Name	Blanchard, David J.		
Sheet	1	of	2	Attorney Docket Number	015280-395100US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DB	A1	US-5,320,956	01-14-1994	Willingham et al.	
	A2	US-5,498,698	03-12-1996	Yamaguchi et al.	
	A3	US-5,723,318	03-03-1998	Yamaguchi et al.	
	A4	US-5,747,654	05-05-1998	Pastan et al.	
	A5	US-6,083,502	07-04-2000	Pastan et al.	
	A6	US-6,153,430	11-28-2000	Pastan et al.	
DB	A7	US-6,809,184 B1	10-26-2004	Pastan et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
DB	A8	WO	92/07081	A2	04-30-1992	Gov. of USA, Dept. Health & Human Services		<input type="checkbox"/>
DB	A9	WO	97/25068	A2	07-17-1997	Gov. of USA, Dept. Health & Human Services		<input type="checkbox"/>
DB	A10	WO	97/34634	A1	09-25-1997	Sloan-Kettering Inst.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB	A11	BRINKMAN, U. et al., "Cloning and Expression of the Recombinant FAb Fragment of Monoclonal Antibody K1 that Reacts with Mesothelin Present on Mesotheliomas and Ovarian Cancers," <u>International Journal of Cancer</u> , May 16, 1997, Vol. 71, No. 4, pp. 638-644	
	A12	CHANG, K., et al., "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers," <u>Proc. Natl. Acad. Sci. USA</u> , January 1996, Vol. 93, pp. 136-140.	
	A13	CHANG, K., et al., "Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium," <u>Cancer Research</u> , Jan. 1, 1992, Vol. 52, No. 1, pp. 181-186.	
	A14	CHOWDHURY, P., et al. "Isolation of Anti-Mesothelin Antibodies From A Phage Display Library," <u>Molecular Immunology</u> , Jan. 1997, Vol. 34, No. 1, pp. 9-20	
	A15	CHOWDHURY, P., et al., "Improving antibody affinity by mimicking somatic hypermutation In vitro," <u>Nature Biotechnology</u> , June 1999, Vol. 17, pp. 568-572.	
DB	A16	COLMAN, P.M., "Effects of amino acid sequence changes on antibody-antigen interactions," <u>Research in Immunology</u> , 1994, Vol. 145, pp. 33-36.	

Examiner Signature		Date Considered	10/31/05
--------------------	--	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BB	A17	DAVIES, J. et al., "Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding," <u>Immunotechnology</u> , 1996, Vol. 2, No. 3, pp. 169-179.	
↓	A18	DORNER, T., et al., "Delineation of Selective Influences Shaping the Mutated Expressed Human Ig Heavy Chain Repertoire," <u>J. Immunol.</u> , 1998, Vol. 160, No. 6, pp. 2831-2841.	
	A19	GREEN, N. et al., "Somatic hypermutation of antibody genes: a hot spot warms up," <u>BioEssays</u> , March 1998, Vol. 20, No. 3, pp. 227-234.	
	A20	HEIDELBERG, Database EMBL (EMPRO) EMBL, March 10, 1998	
	A21	KUBY, J., W.H., "Chapter 6: Antigen-Antibody Interactions," <u>Immunology, Second Edition</u> , Freeman and Company, New York, USA, 1994, pp. 136-134	
	A22	WU, G., et al., "Stepwise in vitro affinity maturation of Vitaxin, an $\alpha\beta_3$ -specific humanized mAb," <u>Proc. Natl. Acad. Sci. US</u> , May 1998, Vol. 95, pp. 6037-6042.	
BB	A23	YAMAGUCHI, N., et al., "A Novel Cytokine Exhibiting Megakaryocyte Potentiating Activity from a Human Pancreatic Tumor Cell Line HPC-Y5," <u>The Journal of Biological Chemistry</u> , 1994, pp. 805-808.	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.